|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||34.53 / 96.59|
Breadth has a small window to improve from the poor and lagging action we saw last week.
In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $64.73, changing hands for $64.82/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Second milestone achieved under 2014 global license agreement with Pfizer
I spent the weekend with thousands of blood disease researchers. This is what happened.
Spark believes temporary treatment with steroids can arrest the immune response before it causes factor IX levels to fall to a point where bleeding risk becomes a problem.
Conference call also scheduled for Monday, Dec. 5 at 8 a.m. ET
The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.
Multi-year collaboration focuses on selecting adeno-associated virus vectors to target debilitating genetic diseases in cells of the retina, liver and central nervous system
Statistically Significant Results for Visual Field Highlighted for the First Time
Free Genetic Test Helps Eligible Patients in U.S. Affected by Certain Progressive Retinal Diseases Get Support and Information
Cramer says be prepared to sell the food group because it is getting too difficult to gauge.
When the market decides only one thing is working, that makes things treacherous for everyone else,
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.